2.565
price down icon0.39%   -0.025
 
loading
Leap Therapeutics Inc stock is traded at $2.565, with a volume of 59,628. It is down -0.39% in the last 24 hours and down -13.42% over the past month. Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
See More
Previous Close:
$2.59
Open:
$2.58
24h Volume:
59,628
Relative Volume:
0.24
Market Cap:
$99.10M
Revenue:
$1.50M
Net Income/Loss:
$-81.41M
P/E Ratio:
-0.394
EPS:
-6.51
Net Cash Flow:
$-43.75M
1W Performance:
-10.73%
1M Performance:
-13.42%
6M Performance:
+2.79%
1Y Performance:
+5.74%
1-Day Range:
Value
$2.55
$2.61
1-Week Range:
Value
$2.55
$2.8999
52-Week Range:
Value
$1.68
$5.00

Leap Therapeutics Inc Stock (LPTX) Company Profile

Name
Name
Leap Therapeutics Inc
Name
Phone
617 252 4343
Name
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Name
Employee
54
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
LPTX's Discussions on Twitter

Compare LPTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LPTX 2.565 99.10M 1.50M -81.41M -43.75M -6.51
VRTX 447.03 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.54 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.40 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.40 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.67 24.49B 3.30B -501.07M 1.03B 11.54

Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-04-21 Initiated Mizuho Buy
Jun-04-21 Resumed Robert W. Baird Outperform
Jun-29-20 Initiated Piper Sandler Overweight
Feb-11-20 Initiated Robert W. Baird Outperform
Nov-15-19 Downgrade Raymond James Outperform → Mkt Perform
Sep-13-19 Resumed Raymond James Outperform
Mar-07-17 Initiated Ladenburg Thalmann Buy
View All

Leap Therapeutics Inc Stock (LPTX) Latest News

pulisher
Nov 19, 2024

HC Wainwright Reaffirms Buy Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal

Nov 18, 2024
pulisher
Nov 15, 2024

Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Balyasny Asset Management L.P. Reduces Stake in Leap Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 13, 2024

Leap Therapeutics Reports Third Quarter 2024 Financial Results - citybiz

Nov 13, 2024
pulisher
Nov 13, 2024

Leap Therapeutics Reports Wider Q3 Loss, Advances Cancer Drug Trials with $62.8M Cash | LPTX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Liquor, Wine, Beer: Which Comes With the Worst Lifestyle? - 69News WFMZ-TV

Nov 13, 2024
pulisher
Nov 07, 2024

Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma

Nov 07, 2024
pulisher
Nov 02, 2024

Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, - GlobeNewswire

Nov 02, 2024
pulisher
Nov 01, 2024

DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post

Nov 01, 2024
pulisher
Oct 27, 2024

Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat

Oct 27, 2024
pulisher
Oct 27, 2024

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance

Oct 27, 2024
pulisher
Oct 25, 2024

Payment processor Finix secures $75m in Series C funding - Electronic Payments International

Oct 25, 2024
pulisher
Oct 18, 2024

Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy - FiercePharma

Oct 18, 2024
pulisher
Oct 17, 2024

Dow Jones notches new record, chip stocks leap higher - Yahoo Finance

Oct 17, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Profire Energy, Inc. (NASDAQ:PFIE) Shares Sold by Marshall Wace LLP - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Makes New Investment in Vivid Seats Inc. (NASDAQ:SEAT) - Defense World

Oct 14, 2024
pulisher
Oct 04, 2024

Venous Leg Ulcers Treatment Market value, Innovations Driving Market Evolution (2024-2036) - Third Eye News

Oct 04, 2024
pulisher
Oct 01, 2024

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - The Malaysian Reserve

Oct 01, 2024
pulisher
Sep 30, 2024

LPTXLeap Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Sep 30, 2024
pulisher
Sep 30, 2024

Venous Leg Ulcers Treatment Market Growth, Size, Research Report and Forecast (2024-2034) - Talented India

Sep 30, 2024
pulisher
Sep 28, 2024

Leap Therapeutics (NASDAQ:LPTX) Share Price Passes Below 50 Day Moving Average of $2.58 - MarketBeat

Sep 28, 2024
pulisher
Sep 25, 2024

Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR

Sep 25, 2024
pulisher
Sep 25, 2024

TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail

Sep 25, 2024
pulisher
Sep 20, 2024

Simplify Asset Management Inc. Has $1.24 Million Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Simplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Meiji Yasuda Asset Management Co Ltd. Has $1.22 Million Stock Position in Hilton Worldwide Holdings Inc. (NYSE:HLT) - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Commonwealth Equity Services LLC Boosts Position in AllianzIM U.S. Large Cap Buffer10 Sep ETF (NYSEARCA:SEPT) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Newmark Security (LON:NWT) Stock Price Crosses Above Two Hundred Day Moving Average of $91.75 - Defense World

Sep 19, 2024
pulisher
Sep 17, 2024

How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle

Sep 17, 2024
pulisher
Sep 16, 2024

Advances in Sickle Cell Disease: New Gene Therapies and Management Strategies - Pharmacy Times

Sep 16, 2024
pulisher
Sep 10, 2024

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St

Sep 10, 2024
pulisher
Sep 06, 2024

Lilly adds to genetic meds push with Genetic Leap alliance - pharmaphorum

Sep 06, 2024
pulisher
Sep 05, 2024

Genetic Leap and Lilly Enter Collaboration to Accelerate Genetic Medicine Development with AI - PR Newswire

Sep 05, 2024
pulisher
Sep 05, 2024

Vera Therapeutics (NASDAQ:VERA) vs. Pivotal Therapeutics (OTCMKTS:PVTTF) Financial Analysis - Defense World

Sep 05, 2024
pulisher
Sep 03, 2024

Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight - PR Newswire UK

Sep 03, 2024
pulisher
Sep 03, 2024

ORKA Stock Price and Chart — NASDAQ:ORKA - TradingView

Sep 03, 2024
pulisher
Sep 02, 2024

Lululemon Athletica (NASDAQ:LULU) Price Target Lowered to $326.00 at Morgan Stanley - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Farther Finance Advisors LLC Has $1.20 Million Stake in Paychex, Inc. (NASDAQ:PAYX) - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Laramide Resources Ltd. (TSE:LAM) Director Buys C$10,200.00 in Stock - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Rothschild Investment LLC Buys Shares of 8,904 Capital Group Growth ETF (NYSEARCA:CGGR) - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Picton Mahoney Asset Management Takes $71,000 Position in American Woodmark Co. (NASDAQ:AMWD) - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Rothschild Investment LLC Makes New Investment in iShares Core MSCI Europe ETF (NYSEARCA:IEUR) - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Farther Finance Advisors LLC Has $1.36 Million Stake in McKesson Co. (NYSE:MCK) - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Intel Co. (NASDAQ:INTC) Shares Purchased by Farther Finance Advisors LLC - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Rothschild Investment LLC Takes Position in BlackRock MuniHoldings Quality Fund II, Inc. (NYSE:MUE) - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Trims Stock Holdings in Universal Health Services, Inc. (NYSE:UHS) - Defense World

Sep 02, 2024
pulisher
Sep 02, 2024

Allspring Global Investments Holdings LLC Sells 103,605 Shares of Wabash National Co. (NYSE:WNC) - Defense World

Sep 02, 2024
pulisher
Aug 31, 2024

Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update - MarketBeat

Aug 31, 2024
pulisher
Aug 27, 2024

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 - GlobeNewswire

Aug 27, 2024

Leap Therapeutics Inc Stock (LPTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):